Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
6 results loaded, newest first. End of these results.
Scholar Rock Holding (NASDAQ: SRRK ) released second-quarter financial results and hosted an earnings call on Thursday. Read the complete transcript below. This transcript is brought to you APIs. For real-time access to our entire catalog, please visit for a consultation. View the webcast at Summary Scholar Rock Holdin
Eli Lilly's experimental combination drug EloraTZP led to an average body weight loss of 23.3% over 48 weeks in a mid-stage trial, compared to 14.8% for its blockbuster Zepbound alone. The company plans to start late-stage trials for EloraTZP in the fourth quarter of 2026.
Novo Nordisk's U.S. head said the company's market share in the U.S. obesity segment has risen about 8 percentage points since January.
Investors and analysts are urging Novo Nordisk CEO Mike Doustdar to outline the company's strategy beyond its blockbuster weight-loss drug Wegovy, calling for medium-term targets and acquisitions to counter looming patent cliffs and competition from Eli Lilly.
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee
Recent setbacks for Danish biotech Zealand Pharma forced analysts to rethink the company's obesity strategy While its drug survodutide disappointed in terms of dropout rates, analysts remain upbeat on its amylin-based drug petrelintide An emerging theme in the weight loss space is the growing acknowledgement of the nee